Abstract: The present invention generally relates to an immunogenic construct, useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism, to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.
Abstract: The invention relates to a novel method for the synthesis of an erythrocyte protein, in which said protein is synthesized in an acellular system for the production of proteins, in the presence of at least one detergent which is non-ionic, of liposomes or of nanodiscs. The invention also relates to compositions comprising the proteins produced in this way.
Type:
Grant
Filed:
October 14, 2016
Date of Patent:
November 24, 2020
Assignees:
Institut National Transfusion Sanguine, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot Paris 7
Abstract: The invention relates to a novel method for the synthesis of an erythrocyte protein, in which said protein is synthesized in an acellular system for the production of proteins, in the presence of at least one detergent which is non-ionic, of liposomes or of nanodiscs. The invention also relates to compositions comprising the proteins produced in this way.
Type:
Application
Filed:
October 14, 2016
Publication date:
January 24, 2019
Applicants:
Institut National Transfusion Sanguine, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot Paris 7